TOGGLE MENU TOGGLE SEARCH Freeline - We are Life Changers 01 / 03 Creating better lives We focus on the development of innovative gene therapies to create better lives for people with chronic diseases. MORE ABOUT US SCROLL Gene therapy — explaining how it works We are transforming our innovative gene technology into potentially life-changing treatments. WATCH OUR ANIMATION Next-generation proprietary AAV platform technology Bringing new innovative therapies to the people who need them. OUR INNOVATION Creating better lives for people living with chronic debilitating disease Working together to make curative treatments a possibility. WORKING WITH PATIENTS AND FAMILIES ABOUT US An experienced management team We have attracted talent from across the world with backgrounds in research, clinical, technical and commercialisation expertise. EXPLORE PATIENTS & FAMILIES Gene therapy explained We are transforming our innovative gene technology into potentially life-changing treatments. EXPLORE CAREERS Working at Freeline It takes a certain sort of person and way of working to start with cutting-edge science and use it to improve people's lives. Our values guide our working culture. EXPLORE LATEST NEWS Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference 23 November 2021 LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline to Participate in Stifel 2021 Virtual Healthcare Conference 10 November 2021 LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results 09 November 2021 Freeline today announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer (CMO) and reported financial results for the third quarter of 2021. READ FULL STORY STOCK INFORMATION PRICE $2.28 CHANGE -$0.01 Dec 2, 2021 4:00 PM ET (Pricing delayed by 20 minutes) MORE STOCK INFORMATION Sign up for news and alerts SIGN UP NOW Get in touch T. Telephone: +44 (0)1438 906870 E. Email: contact@freeline.life Follow us on our social channels About us Innovation Patients & families Healthcare professionals Careers Investors Contact Terms of use Privacy Notice Accessibility Cookie Policy ©2021 Freeline This website uses cookies By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage, and assist in our marketing efforts. Find out more Manage Decline Accept